Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.45 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18159198 | 0.88 | SMN1; SMN2 (0.54) | ALDH1A1TDP1LMNATTRSMN1; SMN2 | |
| SCHEMBL5067716 | 0.85 | MAPT (0.51) | ALDH1A1LMNAHPGDL3MBTL1SMN1; SMN2 | |
| SCHEMBL7274061 | 0.82 | TUBB4A (0.43) | ALDH1A1TDP1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL1531355 | 0.81 | ALDH1A1 (0.53) | ALDH1A1TDP1LMNASIRT6TTR | |
| SCHEMBL18138414 | 0.81 | ALDH1A1 (0.53) | ALDH1A1TDP1LMNASIRT6TTR | |
| SCHEMBL12777062 | 0.81 | ALDH1A1 (0.40) | ALDH1A1TDP1LMNATTRHPGD | |
| SCHEMBL1829547 | 0.80 | MAPT (0.49) | ALDH1A1HPGDL3MBTL1SMN1; SMN2GAA | |
| SCHEMBL14136128 | 0.80 | ALDH1A1 (0.51) | ALDH1A1TDP1LMNASIRT6TTR | |
| SCHEMBL704754 | 0.80 | TTR (0.64) | ALDH1A1TDP1LMNASIRT6TTR | |
| SCHEMBL520466 | 0.80 | ALDH1A1 (0.51) | ALDH1A1TDP1LMNASIRT6TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | disclosed |
| WO-2025245046-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4644387-A2 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12428406-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| WO-2025059074-A1 | BICYCLIC COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-117986235-A | P53-Y220C selective small molecule reactivation agent compound, pharmaceutical composition and application thereof | 长春金赛药业有限责任公司 | 2024-05-07 | — | — | CN | disclosed |
| US-11814373-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814373-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230312539-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230312539-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| WO-2008117175-A2 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | ADDEX PHARMA SA (CH) | 2008-10-02 | — | — | WO | disclosed |
| US-20080234301-A1 | Alpha-4 Integrin Mediated Cell Adhesion Inhibitors for the Treatment or Prevention of Inflammatory Diseases | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-09-25 | — | — | US | disclosed |
| EP-1768984-A1 | THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS | Sunesis Pharmaceuticals, Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| EP-1737826-A1 | ALPHA-4 INTEGRIN MEDIATED CELL ADHESION INHIBITORS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY DISEASES | TANABE SEIYAKU CO., LTD. (JP) | 2007-01-03 | — | — | EP | disclosed |
| WO-2006036266-A1 | THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20060035908-A1 | Thienopyrimidines useful as Aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. | 2006-02-16 | — | — | US | disclosed |
| WO-2005075438-A1 | ALPHA-4 INTEGRIN MEDIATED CELL ADHESION INHIBITORS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY DISEASES | TANABE SEIYAKU CO., LTD. (JP) | 2005-08-18 | — | — | WO | disclosed |
| US-4958026-A | HYPOTENSIVE AGENTS | SCHERING AKTIENGESLLSCHAFT (DE) | 1990-09-18 | — | — | US | disclosed |
| EP-0189473-A1 | NEW DOPAMINE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE AS MEDICINAL PRODUCTS. | SCHERING AG (DE) | 1986-08-06 | — | — | EP | disclosed |
| WO-1986001204-A1 | NEW DOPAMINE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE AS MEDICINAL PRODUCTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234301-A1 | Alpha-4 Integrin Mediated Cell Adhesion Inhibitors for the Treatment or Prevention of Inflammatory Diseases | ITGB4, ITGA4, ICAM1 | ALDH1A1 431/4885TDP1 4352/4885LMNA 1529/4885 |
| US-12428406-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | ALDH1A1 1538/4885TDP1 92/4885LMNA 2920/4885 |
| US-20230312539-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | ALDH1A1 1538/4885TDP1 92/4885LMNA 2920/4885 |
| US-11814373-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | ALDH1A1 1538/4885TDP1 92/4885LMNA 2920/4885 |
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, MDM2 | ALDH1A1 4027/4885TDP1 71/4885LMNA 662/4885 |
| US-20060035908-A1 | Thienopyrimidines useful as Aurora kinase inhibitors | AURKA, AURKB, AURKC | ALDH1A1 2795/4885TDP1 89/4885LMNA 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.